Data Demonstrate Efficacy of 3 PARP Inhibitors in Ovarian Cancer
March 26, 2020 04:44pm
By Angeles Alvarez Secord, MD
Ramez N. Eskander, MD, discusses the current outlook for the frontline treatment landscape in ovarian cancer.
Ramez N. Eskander, MD, assistant clinical professor at Moores Cancer Center, discusses the current outlook for the frontline treatment landscape in ovarian cancer.
Eskander says it is an exciting time right now. Many physicians are still using a platinum doublet as first-line treatment for patients with ovarian cancer. However, the approval of bevacizumab (Avastin) has moved this agent to the frontline as well. This is used in combination with maintenance chemotherapy.
More recent data has also led physicians to incorporate olaparib (Lynparza) into the frontline as a maintenance for patients with a germline or somaticBRCA